Ranbaxy's manufacturing mess results in $606M loss

The manufacturing problems that brought about groundbreaking Department of Justice oversight of Ranbaxy Laboratories ($RBXY) has led to a $500 million charge and a $606 million loss for the fourth quarter. That loss represents the biggest quarterly loss in four years for India's largest generic drugmaker. In addition to significant lapses in its manufacturing practices, the FDA and DOJ found that Ranbaxy had falsified documentation. The consent decree forced the company to upgrade facilities, lose exclusivity on some drugs for a period and even set up an employee whistleblower program. Story | More 

Suggested Articles

Colorado is making a play for a Japanese CDMO in hopes it will invest about $100 million in an empty AstraZeneca plant in Boulder.

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.